MELANIE WAYNE: Open Payments
NPI 1912353657 · EUGENE, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$514 in 17 payments from 10 companies in 2025. Trend: 2023 $3,133 · 2024 $677 · 2025 $514
Food & beverage: $514
| Company | Payments | Amount |
|---|---|---|
| Blueprint Medicines Corporation | 1 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $97 |
| GlaxoSmithKline, LLC. | 2 | $56 |
| Novartis Pharmaceuticals Corporation | 3 | $54 |
| CSL Behring | 3 | $49 |
| AstraZeneca Pharmaceuticals LP | 1 | $34 |
| BioCryst US Sales Co., LLC | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| TerSera Therapeutics LLC | 1 | $20 |
| GENZYME CORPORATION | 1 | $18 |
Products named: AYVAKIT, TAKHZYRO, TRELEGY ELLIPTA, Rhapsido, DUPIXENT, Hizentra, FASENRA, ORLADEYO.
Industry payments across OR — which companies pay providers there.
